Antimicrobials - General Considerations

Classification by Mechanism (organizing framework for whole section)

Cell wall synthesis: β-lactams(penicillins, cephalosporins, carbapenems, monobactams), vancomycin. Cell membrane disruption: polymyxins, daptomycin, amphotericin B. Protein synthesis — 30S: aminoglycosides, tetracyclines. 50S: macrolides, chloramphenicol, clindamycin, linezolid. Nucleic acid synthesis: fluoroquinolones(DNA gyrase/topo IV), rifampicin(RNA polymerase), metronidazole(DNA strand breakage). Antimetabolites: sulfonamides, trimethoprim(sequential folate pathway block).

Bactericidal vs Bacteriostatic

General pattern: cell wall synthesis inhibitors + DNA/membrane-disrupting agents = BACTERICIDAL(β-lactams, aminoglycosides, fluoroquinolones, vancomycin). Most protein synthesis inhibitors = BACTERIOSTATIC(tetracyclines, macrolides, chloramphenicol, clindamycin). EXCEPTION: aminoglycosides = protein synthesis inhibitors that ARE bactericidal(misreading genetic code → non-functional MEMBRANE-DISRUPTING proteins, not just growth arrest).

Clinical: bactericidal REQUIRED(not just preferred) in infective endocarditis + immunocompromised/neutropenic patients(can’t rely on host immunity to finish clearing merely-static organism).

PK/PD Concepts

Concentration-dependent killing(aminoglycosides, fluoroquinolones): efficacy ∝ PEAK conc vs MIC → dosed high-peak, ONCE-DAILY. + post-antibiotic effect(continued suppression even below MIC) further supports less-frequent dosing.

Time-dependent killing(β-lactams, most others): efficacy ∝ DURATION above MIC, not peak → dosed MORE FREQUENTLY/continuous-extended infusion.

Spectrum: narrow(penicillin G, mainly Gram+) vs broad(later cephalosporins, fluoroquinolones, carbapenems). Principle: use NARROWEST effective spectrum when organism/susceptibility known — broad empirical only for genuine diagnostic uncertainty/severe presumed infection(broader use → more collateral resistance selection + flora disruption).

Resistance Mechanisms (shared framework, 4 categories)

1. Enzymatic inactivation: β-lactamases(MOST clinically significant — full detail: Beta-Lactam Antibiotics), aminoglycoside-modifying enzymes.
2. Altered target: PBP mutation(MRSA mecA→PBP2a, ↓β-lactam affinity), ribosomal target methylation(macrolide resistance), DNA gyrase mutation(fluoroquinolone resistance).
3. ↓Drug accumulation: ↓porin expression(esp Gram-negative, already-significant natural outer membrane barrier) + EFFLUX PUMP upregulation(actively exports drug — can cause MULTI-class resistance simultaneously if broad-specificity pump).
4. Metabolic bypass: alternative insensitive enzyme, same function(e.g. alt dihydropteroate synthase insensitive to sulfonamides).

SELECTION, not creation: antibiotics don’t generate resistance mutations de novo — resistant variants PRE-EXIST at low frequency, antibiotic exposure kills susceptible majority → pre-existing resistant organisms survive/proliferate without competition. Basis for antibiotic STEWARDSHIP(↓selection pressure), NOT the “drug teaches bacteria to resist” misconception.

Combination Therapy

Rational reasons(distinct, separately examinable): (1) broaden empirical coverage(unknown organism, urgent) (2) SYNERGISM(e.g. β-lactam weakens cell wall→↑aminoglycoside access to ribosomal target — classic enterococcal endocarditis synergy) (3) prevent resistance emergence DURING therapy(core rationale: multi-drug TB therapy) (4) known polymicrobial infection, no single agent covers all.

NOT automatically superior to monotherapy — costs: ↑toxicity/cost + ANTAGONISM risk(bacteriostatic agent can BLUNT bactericidal agent’s effect by halting active growth/division many bactericidal mechanisms depend on) — caution combining these categories without specific justification.

Clinical Relevance

These frameworks(mechanism classification, bactericidal/bacteriostatic, concentration/time-dependent killing, shared resistance categories) = the LENS for every subsequent Antimicrobials topic — a new drug’s dosing frequency, likely resistance mechanism, and severe/immunocompromised-infection appropriateness can often be PREDICTED from its category here, not memorized fresh per agent.

Classification by Mechanism

The organizing framework for the entire Antimicrobials section — every subsequent topic’s individual drug class fits into one of these mechanistic categories:

1. Cell wall synthesis inhibitors: β-lactams (penicillins, cephalosporins, carbapenems, monobactams), vancomycin
2. Cell membrane disruptors: polymyxins, daptomycin, antifungal polyenes (amphotericin B)
3. Protein synthesis inhibitors
   • 30S ribosomal subunit: aminoglycosides, tetracyclines
   • 50S ribosomal subunit: macrolides, chloramphenicol, clindamycin, linezolid
4. Nucleic acid synthesis inhibitors: fluoroquinolones (DNA gyrase/topoisomerase IV), rifampicin (RNA polymerase), metronidazole (DNA strand breakage)
5. Antimetabolites: sulfonamides, trimethoprim (sequential folate pathway blockade)

Classification by Action Type

Bactericidal (kills bacteria directly) versus bacteriostatic (inhibits growth, relying on the host immune system to clear the now-static organism) is a genuinely important distinction, though the line is not always absolute (some agents are bactericidal at high concentration/against susceptible organisms and bacteriostatic otherwise). As a general, examinable pattern: cell wall synthesis inhibitors and agents disrupting DNA/membrane integrity tend to be bactericidal (β-lactams, aminoglycosides, fluoroquinolones, vancomycin), while most protein synthesis inhibitors are bacteriostatic (tetracyclines, macrolides, chloramphenicol, clindamycin — an exception worth flagging: aminoglycosides are protein synthesis inhibitors that are nonetheless bactericidal, since their mechanism involves misreading of the genetic code producing non-functional, membrane-disrupting proteins rather than mere growth arrest). This distinction matters clinically: bactericidal agents are generally required (not merely preferred) in infective endocarditis and in immunocompromised/neutropenic patients, where an intact host immune response cannot be relied upon to finish clearing a merely growth-arrested organism.

Pharmacokinetic and Pharmacodynamic Concepts

Concentration-dependent versus time-dependent killing determines dosing strategy, a genuinely high-yield pharmacodynamic concept: concentration-dependent killing (aminoglycosides, fluoroquinolones) means efficacy correlates with peak drug concentration relative to the organism’s MIC (minimum inhibitory concentration) — these agents are dosed to achieve a high peak (once-daily, higher-dose regimens), and additionally show a post-antibiotic effect (continued suppression of bacterial growth even after the drug concentration falls below MIC), which further supports less-frequent, high-peak dosing. Time-dependent killing (β-lactams, most other cell-wall/protein-synthesis agents) means efficacy correlates with the duration drug concentration stays above MIC, not the peak — these agents are dosed more frequently (or by continuous/extended infusion) to maximize time-above-MIC rather than pushed to a high single peak.

Spectrum of activity: narrow-spectrum agents (penicillin G, targeting mainly Gram-positive organisms) versus broad-spectrum agents (later-generation cephalosporins, fluoroquinolones, carbapenems, covering Gram-positive, Gram-negative, and sometimes atypical organisms) — the clinical principle, repeatedly tested, is that narrower-spectrum therapy should be used whenever the causative organism and its susceptibility are known or reasonably presumed, reserving broad-spectrum empirical therapy for situations of genuine diagnostic uncertainty or severe/life-threatening presumed infection, precisely because broader-spectrum use drives more collateral resistance selection and disrupts normal flora more extensively.

Mechanisms of Antimicrobial Resistance

A small number of underlying strategies recur across essentially every resistant organism and every drug class, worth understanding as a shared framework rather than memorizing separately per drug:

1. Enzymatic drug inactivation: β-lactamases (hydrolyzing the β-lactam ring — the single most clinically significant resistance mechanism in this section, discussed fully under Beta-Lactam Antibiotics), aminoglycoside-modifying enzymes.
2. Altered target site: penicillin-binding protein mutation (MRSA’s mecA-encoded altered PBP2a, with markedly reduced β-lactam affinity), ribosomal target site methylation (macrolide resistance), DNA gyrase mutation (fluoroquinolone resistance).
3. Reduced drug accumulation: decreased outer membrane porin expression (reducing entry, particularly relevant in Gram-negative organisms, whose outer membrane is already a significant natural barrier many Gram-positive-targeted drugs cannot cross) and efflux pump upregulation (actively exporting the drug back out before it can act, a mechanism contributing to resistance across multiple unrelated drug classes simultaneously when a single broad-specificity efflux pump is upregulated).
4. Metabolic bypass: acquiring an alternative enzyme insensitive to the drug while retaining the same essential metabolic function (e.g. an alternative dihydropteroate synthase insensitive to sulfonamides).

Selection pressure, not creation, is antibiotic use’s role in resistance — antibiotics do not generate resistance mutations de novo in a meaningful sense; resistant variants pre-exist at low frequency within a bacterial population through ordinary mutation, and antibiotic exposure simply kills the susceptible majority, allowing pre-existing resistant organisms to survive and proliferate without competition — the conceptual basis for antibiotic stewardship (minimizing unnecessary/inappropriately broad or prolonged use specifically to reduce this selection pressure) rather than the more intuitive but mechanistically incorrect idea that the drug itself “teaches” bacteria to resist it.

Combination Antimicrobial Therapy

Rational reasons to combine antimicrobials, each distinct and separately examinable: (1) broadening empirical coverage when the causative organism is unknown and the clinical situation is too urgent to wait for culture results; (2) synergism — some combinations produce a killing effect greater than the sum of each drug’s individual effect (e.g. a β-lactam’s cell-wall-weakening action improving an aminoglycoside’s access to its intracellular ribosomal target, the classic synergy exploited in treating enterococcal endocarditis); (3) preventing emergence of resistance during therapy — particularly important where resistant mutants can arise readily against a single agent (the core rationale for multi-drug antitubercular therapy, covered fully under Antitubercular Drugs); (4) treating known polymicrobial infections where no single agent covers every likely organism. Combination therapy is not automatically superior to monotherapy, however, and carries real costs (increased toxicity, cost, and — counterintuitively — the potential for antagonism, where a bacteriostatic agent can blunt a bactericidal agent’s effect by halting the active growth/division that many bactericidal mechanisms depend on, a genuinely examined caution against combining these two categories without a specific justification).

Clinical Relevance

This topic’s frameworks (mechanism-based classification, bactericidal/bacteriostatic distinction, concentration- versus time-dependent killing, and the shared resistance-mechanism categories) are the lens through which every subsequent, individual antimicrobial drug class in this section should be read — a new drug’s dosing frequency, likely resistance mechanism, and appropriateness for a severe/immunocompromised infection can often be predicted correctly from which category it falls into here, rather than needing to be memorized freshly for every individual agent.

• Bacterial cell schematic with each drug class’s mechanistic target marked (cell wall, membrane, 30S/50S ribosome, DNA/RNA synthesis, folate pathway).
• Concentration-dependent vs time-dependent killing curves (drug concentration vs MIC over time) contrasting once-daily-high-peak vs frequent/continuous dosing rationale.
• Four resistance-mechanism categories with one example organism/drug pair each.

Short Essays (2)

Essays (1)

Short Answers (15)

Short Notes (5)

Multiple Choice Questions (1)